Have a personal or library account? Click to login
Serum Levels of Semaphorin 4C in Breast Cancer – Assessment of Prognostic Value and Potential for Monitoring Surgical Treatment Response Cover

Serum Levels of Semaphorin 4C in Breast Cancer – Assessment of Prognostic Value and Potential for Monitoring Surgical Treatment Response

Open Access
|Nov 2024

References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4.
  2. Grancharova G, Aleksandrova-Yankulovska S, Draganova M, et al. Trends in incidence of main types of cancer in Bulgarian women (2010-2021). Eur J Public Health. 2023 Oct 24;33(Suppl 2):ckad160.1556.
  3. Valerianova Z, Atanasov T. (editors). Cancer Incidence in Bulgaria, 2016 & 2017, Volume XXVI. Bulgarian National Cancer Registry. Sofia, Paradigma, 2020.
  4. Aiyappa-Maudsley R, McLoughlin LFV, Hughes TA. Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance. International Journal of Molecular Sciences. 2023; 24(17):13093.
  5. Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021 Jan 15;11(7):3262-3277.
  6. Chen T, Li S, Wang L. Semaphorins in tumor microenvironment: Biological mechanisms and therapeutic progress. Int Immunopharmacol. 2024 May 10;132:112035.
  7. Gurrapu S, Pupo E, Franzolin G, et al. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018 Jul;25(7):1259-1275.
  8. Yang J, Zeng Z, Qiao L, et al. Semaphorin 4C Promotes Macrophage Recruitment and Angiogenesis in Breast Cancer. Mol Cancer Res. 2019 Oct;17(10):2015-2028. doi: 10.1158/1541-7786.MCR-18-0933.
  9. Wei JC, Yang J, Liu D, et al. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C. Clin Cancer Res. 2017 Jan 1;23(1):214-224.
  10. Li H, Li X, Xu S, et al. Semaphorin 4C accelerates disease progression and enables disease detection in breast cancer. Visualized Cancer Medicine. 2023; 4, 6.
  11. Wang Y, Qiao L, Yang J, et al. Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. Cancer Commun (Lond). 2021 Dec;41(12):1373-1386.
  12. Neves Rebello Alves L, Dummer Meira D, Poppe Merigueti L, et al. Biomarkers in Breast Cancer: An Old Story with a New End. Genes (Basel). 2023 Jun 28;14(7):1364.
  13. Alto L T, Terman J R. Semaphorins and their Signaling Mechanisms. Methods in molecular biology (Clifton, N.J.), 2017, 1493, 1–25.
  14. Fard D, Tamagnone L. Semaphorins in health and disease. Cytokine Growth Factor Rev. 2021 Feb;57:55-63.
  15. Jiang J, Zhang F, Wan Y, et al. Semaphorins as Potential Immune Therapeutic Targets for Cancer. Front Oncol. 2022 Jan 27;12:793805.
  16. Franzolin G, Tamagnone L. Semaphorin Signaling in Cancer-Associated Inflammation. Int J Mol Sci. 2019 Jan 17;20(2):377.
  17. Ahammad I. A comprehensive review of tumor proliferative and suppressive role of semaphorins and therapeutic approaches. Biophys Rev. 2020 Oct;12(5):1233-1247.
  18. Bica C, Tirpe A, Nutu A, et al. Emerging roles and mechanisms of semaphorins activity in cancer. Life Sci. 2023 Apr 1;318:121499.
  19. Neufeld G, Mumblat Y, Smolkin T, et al. The role of the semaphorins in cancer. Cell Adh Migr. 2016 Nov;10(6):652-674.
  20. Yang Q, Wang Y, Lu X, et al. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget. 2015 Feb 20;6(5):3268-79.
  21. Borges VF, Hu J, Young C, et al. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer. 2020 Oct 19;6:56.
  22. Jiang D, Chen X, Li X et al. Expression patterns and pathogenesis of Semaphorin class 4 subfamily proteins in solid tumors. Neoplasma. 2024 Feb;71(1):1-12.
  23. Paranthaman P, Veerappapillai S. Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach. Med Oncol. 2023 Feb 23;40(3):105.
  24. Shafique MR, Fisher TL, Evans EE, et al. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul 1;27(13):3630-3640.
  25. Ye SM, Han M, Kan CY, et al. Expression and clinical significance of Sema4C in esophageal cancer, gastric cancer and rectal cancer. Zhonghua Yi Xue Za Zhi. 2012 Jul 24;92(28):1954-8.
  26. Wang Y, Liu J, Li J, et al. Serum semaphorin4C as an auxiliary diagnostic biomarker for breast cancer. Clin Transl Med. 2021 Aug;11(8):e480.
DOI: https://doi.org/10.2478/amb-2024-0070 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Language: English
Page range: 1 - 7
Submitted on: Jun 19, 2024
Accepted on: Jun 27, 2024
Published on: Nov 23, 2024
Published by: Sofia Medical University
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Ts. Popov, S. Maslyankov, A. Arabadzhiev, M. Sokolov, S. Kandilarova, published by Sofia Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.